Patent intelligence · US
US 12138301
Compounds including a mutant KRAS sequence and a lipid and uses thereof
Compounds including a mutant KRAS sequence and a lipid and uses thereof
Patent details — US 12138301
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 12, 2024
- Expiration
- Nov 7, 2044
- Applicant
- Elicio Therapeutics, Inc.
- Claims
- 34
- CPC classes
- A61K, A61K2039/545, A61K2039/55561, A61K31/7088
Quick answer
US 12138301 (Compounds including a mutant KRAS sequence and a lipid and uses thereof) is held by Elicio Therapeutics, Inc.. Status: granted. Granted Nov 12, 2024. Expires Nov 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Elicio Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 34
- CPC classes
- A61K, A61K2039/545, A61K2039/55561, A61K31/7088, A61K39/001164, A61K39/39
More from Elicio Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12138301?
US 12138301 (Compounds including a mutant KRAS sequence and a lipid and uses thereof) is held by Elicio Therapeutics, Inc.. Status: granted. Granted Nov 12, 2024. Expires Nov 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12138301?
Elicio Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12138301 expire?
Our index shows an expiration date of Nov 7, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.